Assumptions: Since there is no individual data on each patient performance and their membership in the efficacy biomarker group as per page 12 & 13, we extrapolate individual performance in linear fashion ( doubtful yet the only tool available ) to 148 weeks. For some data is given up to 109 weeks: patients 1014, 2006, … Continue reading $AVXL : After Digesting CTAD 2018 Data More Fancy Colorful Plots.

I dismissed any talk about possibility of success of monoclonal antibodies in targeting Amyloid Plaque in Alzheimer.  Mea Culpa Maxima! Sometimes one has to make about-face, and acknowledge that BIIB037 does prove something.  In Alzheimer model, from this reference Ref 1 3D model of Alzheimer in vitro , the Amyloid Plaque appears after incubation and causes the … Continue reading $BIIB $AVXL I confess: I dismissed BIIB037 as irrelevant, yet I still can be right….

The most nagging question for my fellow $AVXL investors is whether ANAVEX 2-73 will get approved and is there enough efficacy to get to that point? Today (10-26-2018) at CTAD Barcelona 2018 $AVXL released information on the results of dosing patients for 148 weeks ( 2 years 10 months ).  The data provided can be found … Continue reading Thank God it is Friday! $AVXL ANAVEX 2-73 after 148 weeks.